Shanghai Xingtai Pharmaceutical Technology

Shanghai Xingtai Pharmaceutical Technology is a China-based biotechnology company and a wholly-owned subsidiary of Fosun Pharma. The company focuses on the research and development of innovative small molecule drugs, particularly in the fields of oncology and rare diseases. Its lead candidate, FCN-159, is a highly selective MEK1/2 inhibitor currently in late-stage clinical development for indications such as neurofibromatosis type 1 (NF1) and various solid tumors. Shanghai Xingtai leverages its parent company's extensive resources to advance its pipeline from discovery through clinical trials. The company is headquartered in Shanghai and plays a key role in Fosun Pharma's innovative drug R&D ecosystem. It is dedicated to addressing unmet medical needs through the development of targeted therapies.